血清NLRP3及其效应分子与高血糖妇女怀孕结果之间的关系
Ning Han1, Zili Yuan1, Hongyang Zhao1
1Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
概括
患有高血糖症的孕妇血清NLRP3炎症组分升高与胰岛素抵抗相关,并预测妊娠不良结果,如早产和高血压疾病. 这些发现突出了NLRP3作为监测高风险怀孕的潜在生物标志物.
科学领域:
- 生殖医学 生殖医学
- 免疫学 免疫学 免疫学
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 怀孕期间高血糖,包括孕期糖尿病 (GDM) 和孕期糖尿病 (PGDM),与不良的孕产妇和新生儿结局有关.
- 作为先天免疫的关键组成部分的NLRP3炎症酶已被涉及到代谢炎症,但其在与怀孕相关的高血糖症中的作用需要进一步阐明.
研究的目的:
- 在患有高血糖症的孕妇中研究NLRP3炎症酶及其效应分子 (Caspase-1,IL-1β,IL-18) 的血清水平.
- 探索这些标记物,胰岛素抵抗和怀孕结果之间的关联.
- 评估NLRP3炎症酶对妊娠不良结果的预测价值.
主要方法:
- 血清样本是在怀孕中期从患有GDM,PGDM和正常葡萄糖耐受性 (NGT) 的妇女收集的.
- 测量了NLRP3,卡斯帕酶-1,IL-1β和IL-18的水平.
- 分析了与空腹血糖,空腹胰岛素,胰岛素抵抗指数和怀孕结果的关系.
- 使用接收器操作特征 (ROC) 曲线分析来评估预测值.
主要成果:
- 与NGT组相比,GDM和PGDM组的血清NLRP3炎症组分显著增加.
- 这些升高的水平与胰岛素抵抗的标志物 (禁食血糖,禁食胰岛素,HOMA-IR) 有积极的相关性.
- 在高血糖组中,不良结果 (早产,高血压疾病,新生儿低血糖症,大血糖症) 的发生率更高.
- 结合的NLRP3炎症酶标志物显示出对不良妊娠结果的高预测准确度 (AUC范围从0.72到0.84).
结论:
- 在患有高血糖症的孕妇中,血清NLRP3炎症酶和效应分子的增加与胰岛素抵抗有关.
- 这些标志物作为潜在的预测者,为不良的妊娠结果.
- 准NLRP3炎症酶途径可能为管理高血糖相关妊娠并发症提供治疗途径.
相关概念视频
01:20Pathophysiology of Diabetes
937
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
937
01:22Diabetes Mellitus: Type 2 and Gestational
2.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.4K
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
92
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
92
01:24Glucagon-like Receptor Agonists
322
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
322
01:15Hypoglycemia and Glucagon
263
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
263